Eton Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Eton Pharmaceuticals, Inc. (ETON) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 550.47 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Shareholders' Equity
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-13
- Eton Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 45.80K shares, a 162.09% increase year-over-year.
- Eton Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 504.67K shares, a 13.39% increase year-over-year.
- Eton Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 0.00 shares, a 100.00% decline year-over-year.
- Eton Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 8.50K shares, a 78.75% decline year-over-year.
- Eton Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 471.06K shares, a 70.94% decline from fiscal 2024.
- Eton Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 1.62M shares, a 46.27% increase from fiscal 2023.
- Eton Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 1.11M shares.
- Eton Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2018 was 225.00K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 45.80K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | 550.47K shares 10-Q · filed 2026-08-13 | 550.47K shares derived: sum of 3 quarters · filed 2026-08-13 | 558.97K shares derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | 504.67K shares 10-Q · filed 2026-05-14 | 504.67K shares derived: sum of 2 quarters · filed 2026-05-14 | 513.17K shares derived: sum of 3 quarters · filed 2026-05-14 | 530.65K shares derived: sum of 4 quarters · filed 2026-05-14 |
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | 8.50K shares derived: sum of 2 quarters · filed 2026-03-19 | 25.98K shares derived: sum of 3 quarters · filed 2026-03-19 | 471.06K shares 10-K · filed 2026-03-19 |
| 2025-09-30 | 8.50K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | 25.98K shares derived: sum of 2 quarters · filed 2025-11-06 | 471.06K shares 10-Q · filed 2025-11-06 | 581.06K shares derived: sum of 4 quarters · filed 2025-11-06 |
| 2025-06-30 | 17.48K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | 462.56K shares 10-Q · filed 2025-08-07 | 572.56K shares derived: sum of 3 quarters · filed 2025-08-07 | 612.56K shares derived: sum of 4 quarters · filed 2025-11-06 |
| 2025-03-31 | 445.08K shares 10-Q · filed 2025-05-13 | 555.08K shares derived: sum of 2 quarters · filed 2025-05-13 | 595.08K shares derived: sum of 3 quarters · filed 2025-11-06 | 625.08K shares derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-12-31 | 110.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | 150.00K shares derived: sum of 2 quarters · filed 2025-11-06 | 180.00K shares derived: sum of 3 quarters · filed 2025-11-06 | 1.62M shares 10-K · filed 2025-03-18 |
| 2024-09-30 | 40.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | 70.00K shares derived: sum of 2 quarters · filed 2025-11-06 | 1.51M shares 10-Q · filed 2025-11-06 | 1.54M shares derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | 30.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | 1.47M shares 10-Q · filed 2025-08-07 | 1.50M shares derived: sum of 3 quarters · filed 2025-08-07 | 1.52M shares derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | 1.44M shares 10-Q · filed 2024-05-09 | 1.47M shares derived: sum of 2 quarters · filed 2024-05-09 | 1.49M shares derived: sum of 3 quarters · filed 2024-05-09 | 1.50M shares derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-12-31 | 30.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | 45.00K shares derived: sum of 2 quarters · filed 2024-03-14 | 55.00K shares derived: sum of 3 quarters · filed 2024-03-14 | 1.11M shares 10-K · filed 2024-03-14 |
| 2023-09-30 | 15.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 25.00K shares derived: sum of 2 quarters · filed 2023-11-09 | 1.08M shares 10-Q · filed 2023-11-09 | |
| 2023-06-30 | 10.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | 1.06M shares 10-Q · filed 2023-08-10 | ||
| 2023-03-31 | 1.05M shares 10-Q · filed 2023-05-11 | |||
| 2019-03-31 | 617.50K shares 10-Q · filed 2019-05-07 | 707.50K shares derived: sum of 2 quarters · filed 2019-05-07 | ||
| 2018-12-31 | 90.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-25 | 225.00K shares 10-K · filed 2019-03-25 | ||
| 2018-09-30 | 135.00K shares 10-Q · filed 2018-12-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |